Hims and Hers stock price target maintained at $23 by BofA Securities

Hims & Hers set its GLP-1 subscription at $149/month and BofA reiterated a Neutral rating with a $23 price target. The stock trades at $20.35 (down 64% over six months, down 14% last week) as BofA warns of unclear standalone medicine margins, uncertain customer-acquisition costs and an estimated 31% contraction of the GLP-1 franchise in 2026. Offsetting this, a partnership to offer Novo Nordisk’s FDA-approved GLP-1s (including Wegovy/Ozempic and a Wegovy pill) triggered analyst upgrades, a 49% surge on Monday and 10% on Tuesday, and Novo dropping its lawsuit — monitor subscription economics and CAC for near-term valuation risk.

Analysis

The Novo partnership is a structural de-risk for channel access but creates a two-way margin dynamic for HIMS: branded supply reduces black‑market pricing variance but raises unit COGS and ties fulfillment to manufacturer allocation windows. Expect a multi-quarter transition where gross margin per prescription falls while lifetime value (LTV) may rise if retention improves; the net outcome depends on whether HIMS can compress CAC by layering clinical/telehealth services around branded fills.

Second‑order winners include large pharmacy/fulfillment partners able to absorb allocation swings and capture higher per‑prescription fulfillment fees; losers are smaller compounding providers and pure-play low‑cost telehealth operators that cannot match branded supply or integrated care. Watch inventory flows and route‑to‑market metrics (days‑on‑hand, fill success, denial rates) — these will lead indicators for churn and ARPU two to three months before revenue prints.

Key risks are payer pushback and adjudication complexity as payors draw lines between compounding and branded GLP‑1 coverage, which could compress reimbursement or create step therapy demands; conversely, if HIMS proves better at converting episodic users into chronic care patients, the embedded clinical revenue could more than offset higher drug costs over 12–24 months. Sentiment moves will remain binary in the near term: expect pronounced volatility into the next two earnings cycles as markets re‑price CAC and persister metrics.

Contrarian angle: the market is pricing only near‑term gross margin pressure and ignoring the optionality of HIMS monetizing longitudinal care (weight management programs, subscription upsells, metabolic coaching) where per‑patient economics could exceed current drug margin shortfalls. If management can hold CAC near current levels while improving retention by even 10–15% over 12 months, upside to consensus EBITDA is asymmetric and could trigger multiple expansion from current depressed comparables.

Key Decisions for Investors

• Tactical long HIMS call spread (6–9 months): buy HIMS Jul‑2026 call spread (entry beneath $22 spot). Risk = premium paid; Reward potential ~2–4x if subscriptions stabilize and multiple re-rates by earnings. Exit: take profits at 50–75% of max or if monthly subscription churn rises >5% sequentially.
• Protective collar for holders: buy 6‑month HIMS puts (OTM) and sell 9–12 month covered calls to fund cost. This caps downside through the next two earnings cycles while allowing upside if the branded transition demonstrates better retention; target cost <3% notional per quarter.
• Event short catalyst (speculative): buy HIMS 3‑month put spread if management flags larger than expected CAC or shows supply/fulfillment misses in monthly KPIs (trigger = >7% month‑over‑month subscription decline). Risk limited to premium; payoff if market reprices 20–40% lower on guidance reset.
• Long NVO as asymmetric hedge (2–3% portfolio weight): buy NVO LEAPs or stock to capture secular GLP‑1 demand growth and to hedge downside to branded pricing upside. Rationale: NVO benefits from volume and channel diversification even if smaller telehealth players re‑price.